print this page | email this page
New Glaucoma Medication
In September 2006, the U.S. Food and Drug Administration (FDA) approved Travatan® Z, marketed by Alcon, Inc. in Fort Worth, TX.
The active ingredient in Travatan® Z is the same found in the original Travatan®: travoprost, a prostaglandin analog. Travatan® Z is a new formulation that replaces the preservative benzalkonium chloride (BAK) with Sofzia ™, a robust ionic buffered preservative system that is gentle to the ocular surface.
FDA approval of Travatan® Z was based on a double-masked, multi-center study which has been accepted for publication by the Journal of Glaucoma.